» Articles » PMID: 33298750

Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic

Overview
Journal J Addict Med
Specialty Psychiatry
Date 2020 Dec 10
PMID 33298750
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The Grayken Center for Addiction at Boston Medical Center includes programs across the care continuum for people with substance use disorders (SUDs), serving both inpatients and outpatients. These programs had to innovate quickly during the COVID-19 outbreak to maintain access to care. Federal and state regulatory flexibility allowed these programs to initiate treatment for people experiencing homelessness and maximize patient safety through physical distancing practices. Programs switched to telehealth with high levels of acceptability and patient retention. Some programs also maintained some face-to-face clinic visits to see patients with complex problems and to provide injectable medications. Text-messaging proved invaluable with adolescent and young adult clients, and a mobile-health outreach program was initiated to reach mother/child dyads affected by SUDs. A 24-hour hotline was implemented to support seamless access to treatment for hundreds released from incarceration early due to the pandemic. Boston Medical Center also launched the COVID Recuperation Unit to allow patients experiencing homelessness to recover from mild to moderate COVID-19 infection in an environment that took a harm-reduction approach to SUDs and provided rapid initiation of medication treatment. Many of these innovations increased access to treatment and retention of patients during the pandemic. Maintaining the revised regulations would allow flexibility to provide telehealth, extended prescriptions, and remote access to buprenorphine initiation to support and engage more patients with SUDs.

Citing Articles

A qualitative exploration of triggers for alcohol use and access to support during the COVID-19 pandemic among people identifying as problem drinkers in the United Kingdom.

Yaqubi H, May T, Burton A Drug Alcohol Rev. 2025; 44(3):858-870.

PMID: 39935079 PMC: 11886483. DOI: 10.1111/dar.14013.


Substance Use Disorder Treatment Programs during a Health Crisis: Response to the COVID-19 Pandemic and Future Implications.

Baloh J, Charton H, Curran G Subst Use Misuse. 2023; 58(14):1855-1865.

PMID: 37722809 PMC: 10872742. DOI: 10.1080/10826084.2023.2257305.


Assessment of COVID-19-Driven Changes in an Integrated OBGYN-Addiction Treatment Clinic and Future Implications.

Smarony S, Parlier-Ahmad A, Shadowen H, Thakkar B, Scheikl M, Martin C J Addict Med. 2023; 17(3):e183-e191.

PMID: 37267180 PMC: 10248187. DOI: 10.1097/ADM.0000000000001122.


Use of Video Directly Observed Therapy and Characteristics Associated With Use Among Patients Treated With Buprenorphine in an Office-based Setting.

Radick A, James J, Leroux B, Kim T, Saxon A, Samet J J Addict Med. 2023; 17(3):300-304.

PMID: 37267172 PMC: 10123169. DOI: 10.1097/ADM.0000000000001103.


Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study.

Scott G, Turner S, Lowry N, Hodge A, Ashraf W, McClean K BMJ Open. 2023; 13(3):e069857.

PMID: 36944465 PMC: 10032386. DOI: 10.1136/bmjopen-2022-069857.